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A b s t r a c t
The present study was done to investigate the 
concordance between the HER2 status measured 
by immunohistochemical analysis (HercepTest, 
DAKO, Carpinteria, CA) and fluorescence in 
situ hybridization (FISH; HER2 FISH pharmDx, 
DAKO) in a large study cohort (n = 681) of patients 
with high-risk breast cancer. A high agreement 
between immunohistochemical and FISH results was 
demonstrated. For the whole study population, the 
agreement between the 2 assays was 93.1% with a 
corresponding κ coefficient of 0.85. When the equivocal 
immunohistochemical 2+ cases were excluded from the 
analysis (n = 79), the agreement increased to 95.0% 
with a κ coefficient of 0.90. When the cutoff value for 
amplified/nonamplified cases in the HER2 FISH assay 
was increased from 2.0 to 2.2 as recommended in the 
American Society of Clinical Oncology/College of 
American Pathologists guidelines, the concordance 
between the 2 assays was 94.3% with a κ coefficient of 
0.87 in the whole study population. When the equivocal 
immunohistochemical 2+ cases were excluded from this 
analysis, the concordance is similar (95.7% with a 
κ coefficient of 0.91).
Within the last decade, HER2 has been shown to be an 
important target in the treatment of cancer, such as breast 
and gastric cancer.1,2 The determination of HER2 status 
serves as a critical predictive test for treatment with the 
monoclonal antibody trastuzumab (Herceptin, Genentech/
Roche, Basel, Switzerland) and the tyrosine kinase inhibitor 
lapatinib (Tykerb, GlaxoSmithKline, Brentford, England).3 
The relationship between positive HER2 status and outcome, 
when treating with these HER2 inhibitors, has been demon-
strated in a number of clinical studies.4-9 Furthermore, several 
new compounds directed toward HER2, especially selective 
tyrosine kinase inhibitors, are in clinical development,10 
and, thus, the need for the identification of patient subgroups 
expressing different levels of the HER2 protein and gene is 
expected to increase in the years to come.
The HER2 gene (also known as ERBB2) is a proto-onco-
gene located on chromosome 17. The HER2 gene encodes 
a 185-kDa transmembrane tyrosine kinase receptor protein, 
which is a member of the HER family (HER1-4).1,11 Slamon 
et al12 demonstrated that amplification of the HER2 gene in 
patients with breast cancer negatively impacted the recurrence 
of disease and survival. These initial data have been confirmed 
in a large number of studies, and a recent meta-analysis based 
on data from 39,730 patients with breast cancer showed an 
overall HER2+ rate of 22.2% and an adverse clinical outcome 
with a mean relative risk for overall survival of 2.74.1 Slamon 
et al13 also demonstrated that HER2 protein overexpression 
is almost always a direct consequence of gene amplification 
with a high correlation between the gene and the protein.
A number of slide-based assays are available for the 
detection of overexpression of the HER2 protein, measured by 
immunohistochemical studies, and amplification of the HER2 
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gene, measured by fluorescence in situ hybridization (FISH) 
and chromogenic in situ hybridization or silver in situ hybrid-
ization.1,3 The in situ hybridization and immunohistochemical 
tests are used for the selection of patients with breast cancer 
who might benefit from treatment with an HER2 inhibitor, 
and, hence, it is important to demonstrate high concordance 
between these types of assays. A number of concordance 
studies have been performed between in situ hybridization 
and immunohistochemical analysis, but, in many cases, the 
conclusions from these studies have been hampered by the 
relatively small number of patients included.14-22 The aims 
of the present study were to investigate the concordance 
between immunohistochemical analysis and FISH in a large 
cohort of patients with high-risk breast cancer and to explore 
the influence on the agreement between the 2 types of assays 
in relation to an increase of the cutoff value for amplified/
nonamplified for FISH from 2.0 to 2.2, as recommended by 
the American Society of Clinical Oncology (ASCO)/College 
of American Pathologists (CAP) guidelines.23
Materials and Methods
Samples
Formalin-fixed, paraffin-embedded tumor blocks from 
681 patients with primary high-risk breast cancer in the 
Danish part of the DBCG 89D protocol were used in the 
study. The design of this study has been described extensively 
elsewhere.24 Consecutive serial sections were cut at 4 μm 
from the paraffin-embedded tumors for immunohistochemi-
cal analysis and FISH and stored cold until staining was per-
formed. A slide stained with H&E, prepared from each block, 
was used to confirm the invasive nature of the carcinoma. 
All samples were collected in 2001 and analyzed from 2001 
to 2003. No further testing has been done in relation to the 
present study.
Immunohistochemical Analysis
Immunohistochemical analysis was performed using 
the HercepTest kit (DAKO, Carpinteria, CA). The sections 
were stained within 5 days from cutting using an autostainer 
according to the procedures specified by the manufacturer of 
the kit. Positive control samples supplied with the kit were 
included, as were in-house control samples together with 
a negative control sample for each case. The results were 
scored as 0, 1+, 2+, and 3+ according to the recommenda-
tions for the HercepTest (10% cutoff). The examinations of 
the immunohistochemical and FISH slides were performed 
in a blinded manner, ie, data concerning tumor size, malig-
nancy grade, receptor status, number of positive lymph 
nodes, therapy, and clinical outcome data were unknown to 
the examiner.
FISH Analysis
FISH was performed using the HER2 FISH pharmDx 
Kit (DAKO) according to the manufacturer’s instructions. 
In cases of ductal carcinoma with an in situ component, the 
negative control slide for HercepTest was used to mark the 
invasive areas to avoid any possibility of including the in situ 
component. Up to 60 gene signals were counted in nuclei with 
identifiable boundaries, as previously described.25 Optimally, 
only signals distinctly separated from each other were includ-
ed, but in case of clusters due to high levels of amplification, 
the number was estimated. The ratio was calculated as the 
number of signals for the gene probe divided by the number 
of signals for the centromere 17 (CEN-17) probe.
Statistical Analysis
The concordance between the 2 assays was estimated by 
calculating the overall percentage of agreement (concordance) 
and the κ coefficient. The 95% confidence interval (CI) 
was estimated for κ. A κ coefficient of more than 0.80 will 
correspond to an almost perfect agreement as per the scale 
proposed by Landis and Koch.26 The concordance analyses 
were performed with 2 different cutoff values for HER2 gene 
amplification: 2.0 or more and 2.2 or more. For these 2 cutoff 
values, the following cohorts were analyzed: (1) all cases with 
a HercepTest score of 0, 1+, 2+, or 3+ (n = 681) and (2) all 
cases with a HercepTest score of 0, 1+, or 3+ (n = 602). The 
reason for excluding the equivocal 2+ cases in the second 
analysis is given in the ASCO/CAP guideline for HER2 test-
ing, stating that the equivocal cases are not expected to fulfill 
the 95% concordant requirements; rather they should be sub-
jected to a confirmatory test.23
Ethics
The study was conducted according to the Helsinki 
Declaration and was approved by The Danish Scientific 
Ethical Committees before initiation.
Results
All Cases With HercepTest Scores of 0, 1+, 2+, and 3+
Of the 681 specimens included in this analysis, 358 cases 
(52.6%) were classified by immunohistochemical analysis 
as negative (0 or 1+), 79 cases (11.6%) as equivocal (2+), 
and 244 cases (35.8%) as positive (3+). For FISH, 434 cases 
(63.7%) were classified as negative (nonamplified) and 247 
(36.3%) cases as positive (amplified). The distribution of the 
HercepTest scores in relation to HER2 FISH status is shown 
in ❚Table 1❚. The cutoff value for amplified/nonamplified in 
this analysis was 2.0 or more. With regard to the concordance 
between the immunohistochemical and FISH scores, this was 
defined as cases that were immunohistochemically negative/
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FISH nonamplified or immunohistochemically positive/FISH 
amplified. In this first analysis, the immunohistochemical cases 
with a 2+ score were classified as negative. The cross-tabula-
tion of HER2 immunohistochemical status in relation to HER2 
gene status from FISH is also shown in Table 1. Of the cases, 
25 (3.7%) were scored as negative by immunohistochemical 
analysis and positive/amplified by FISH, and 22 cases (3.2%) 
were scored as positive by immunohistochemical analysis and 
negative/nonamplified by FISH. The concordance between the 
2 assays was 93.1% with a corresponding κ coefficient of 0.85 
(95% CI, 0.81-0.89). A κ coefficient of 0.85 corresponds to 
almost perfect agreement. The relation between the HercepTest 
score and HER2 gene status by FISH (cutoff ≥2.0) is shown in 
❚Figure 1❚ for the whole study population (n = 681).
In the subsequent analysis, the cutoff value for amplified/
nonamplified was increased to 2.2 or more, which moved 8 
cases from amplified to nonamplified. For this analysis, the 
distribution of the HercepTest score in relation to HER2 gene 
status is shown in ❚Table 2❚. Also in this analysis, immunohis-
tochemical cases with a 2+ score were classified as negative. 
The cross-tabulation of HER2 immunohistochemical status 
in relation to HER2 gene status by FISH is also shown in 
Table 2. The concordance between the 2 assays increased to 
94.3% with a corresponding κ coefficient of 0.87 (95% CI, 
0.84-0.91), which corresponds to almost perfect agreement. 
The relationship between the HercepTest score and HER2 
gene status by FISH (cutoff ≥2.2) is shown in ❚Figure 2❚ for 
the whole study population (n = 681).
All Patients With HercepTest Scores of 0, 1+, and 3+
When the 2+ equivocal immunohistochemical cases were 
excluded from the study population, the number of cases 
decreased to 602. The distribution of the HercepTest score in 
relation to HER2 gene status, when the cutoff value for ampli-
fied/nonamplified was 2.0 or more, is shown in ❚Table 3❚. 
❚Table 1❚
Cross-Tabulation of HercepTest Score and HER2 
Immunohistochemical Status vs HER2 Gene Status by FISH 
(Cutoff ≥2.0)
 HER2 FISH Status
 Nonamplified Amplified Total
HercepTest   
   0 106 0 106
   1+ 244 8 252
   2+ 62 17 79
   3+ 22 222 244
   Total 434 247 681
HER2 immunohistochemical status   
   Negative (0, 1+, 2+) 412 25 437
   Positive (3+) 22 222 244
   Total 434 247 681
FISH, fluorescence in situ hybridization.
❚Table 2❚
Cross-Tabulation of HercepTest Score and HER2 
Immunohistochemical Status vs HER2 Gene Status From 
FISH (Cutoff ≥2.2)
   HER2 FISH Status
 Nonamplified Amplified Total
HercepTest   
   0 106 0 106
   1+ 248 4 252
   2+ 66 13 79
   3+ 22 222 244
   Total 442 239 681
HER2 immunohistochemical status   
   Negative (0, 1+, 2+) 420 17 437
   Positive (3+) 22 222 244
   Total 442 239 681
FISH, fluorescence in situ hybridization.
❚Figure 1❚ The relationship between HercepTest score and 
HER2 gene status by fluorescence in situ hybridization (FISH) 






















❚Figure 2❚ The relationship between HercepTest score and 
HER2 gene status by fluorescence in situ hybridization (FISH) 
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The cross-tabulation of HER2 immunohistochemical status in 
relation to HER2 gene status by FISH for this cohort is also 
shown in Table 3. Of the cases, 8 (1.3%) were scored as nega-
tive by immunohistochemical analysis and positive/amplified 
by FISH, and 22 cases (3.7%) were scored as positive by 
immunohistochemical analysis and negative/nonamplified by 
FISH. The concordance between the 2 assays was 95.0% with 
a corresponding κ coefficient of 0.90 (95% CI, 0.86-0.93), 
which corresponds to almost perfect agreement. The relation-
ship between the HercepTest score and HER2 gene status by 
FISH (cutoff ≥2.0) is shown in ❚Figure 3❚ (n = 602).
Also for this cohort, a subsequent analysis was performed 
in which the cutoff value for amplified/nonamplified was 
increased to 2.2 or more, which moved 4 cases from ampli-
fied to nonamplified. For this analysis, the distribution of the 
HercepTest score in relation to HER2 gene status is shown in 
❚Table 4❚. The cross-tabulation of HER2 immunohistochemi-
cal status in relation to HER2 gene status by FISH is also 
shown in Table 4. Compared with a cutoff of 2.0 or more, the 
concordance between the 2 assays increased to 95.7% with 
a corresponding κ coefficient of 0.91 (95% CI, 0.87-0.94), 
which again corresponds to almost perfect agreement. The 
relationship between the HercepTest score and HER2 gene 
status by FISH (cutoff ≥2.2) is shown in ❚Figure 4❚ (n = 602).
Discussion
In the present study, the frequency of HER2 gene ampli-
fication and overexpression of the HER2 protein was found 
to be around 36%, which is somewhat higher than usually 
observed in patients with breast cancer. In a recent meta-analysis, 
comprising nearly 40,000 patients, Ross et al1 found an HER2 
❚Table 4❚
Cross-Tabulation of HercepTest Score and HER2 
Immunohistochemical Status vs HER2 Gene Status From 
FISH (Cutoff ≥2.2) With the Immunohistochemically 2+ 
(Equivocal) Cases Excluded
 HER2 FISH Status
 Nonamplified Amplified Total
HercepTest   
   0 106 0 106
   1+ 248 4 252
   3+ 22 222 244
   Total 376 226 602
HER2 immunohistochemical status   
   Negative (0, 2+) 354 4 358
   Positive (3+) 22 222 244
   Total 376 226 602
FISH, fluorescence in situ hybridization.
❚Table 3❚
Cross-Tabulation of HercepTest Score and HER2 
Immunohistochemical Status vs HER2 Gene Status From 
FISH (Cutoff ≥2.0) With the Immunohistochemically 2+ 
(Equivocal) Cases Excluded
 HER2 FISH Status
 Nonamplified Amplified Total
HercepTest   
   0 106 0 106
   1+ 244 8 252
   3+ 22 222 244
   Total 372 230 602
HER2 immunohistochemical status   
   Negative (0, 2+) 350 8 358
   Positive (3+) 22 222 244
   Total 372 230 602
FISH, fluorescence in situ hybridization.
❚Figure 3❚ The relationship between HercepTest score and 
HER2 gene status by fluorescence in situ hybridization (FISH) 
(cutoff ≥2.0), when the immunohistochemically 2+ equivocal 
cases are excluded from analysis (n = 602).
❚Figure 4❚ The relationship between HercepTest score and 
HER2 gene status by fluorescence in situ hybridization (FISH) 
(cutoff ≥2.2), when the immunohistochemically 2+ equivocal 
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positivity rate of 22.2%. The explanation for the high HER2+ 
rate in the present study is to be found in the cohort studied.24 
All patients in the DBCG-89D study were high-risk patients 
who were premenopausal with tumor greater than 5 cm, or 
with positive axillary lymph nodes, and with steroid receptor–
negative or steroid receptor–unknown tumor; postmenopausal 
with tumor greater than 5 cm, or with positive axillary lymph 
nodes, and with steroid receptor–negative tumor; or premeno-
pausal with tumor less than 5 cm, and with negative axillary 
lymph nodes, and with ductal carcinoma with anaplasia degree 
II-III. Hence, a higher HER2+ rate is clearly anticipated.1
High overall agreement between immunohistochemical 
analysis (HercepTest) and FISH (HER2 FISH pharmDx Kit) 
was demonstrated in the present study when the HER2 immu-
nohistochemically equivocal cases (2+) were included and 
when they were excluded from the analyses. The agreement 
between the 2 assays was 93.1% for the whole study popula-
tion (n = 681). When the immunohistochemically equivocal 
cases (2+) were excluded from the analysis (n = 79), the 
agreement increased to 95.0%. The κ coefficients for the 2 
analyses were 0.85 and 0.90, respectively, which corresponds 
to almost perfect agreement in both situations.26
When the cutoff value for HER2 FISH was increased from 
2.0 to 2.2, the concordance between the 2 assays was 94.3% 
with a κ coefficient of 0.87 in the whole study population. 
Here, a total of 8 cases were moved from being amplified to 
nonamplified by HER2 FISH. When the immunohistochemi-
cally equivocal cases (2+) were subsequently excluded from 
the analysis, the concordance increased to 95.7% with a κ 
coefficient of 0.91. Again, the κ coefficients for these analyses 
correspond to almost perfect agreement.26 However, for this 
part of the study, it should be underlined that the scoring of 
the immunohistochemical slides was not in agreement with 
the ASCO/CAP guidelines with regard to uniform intense 
membrane staining in more than 30% of the tumor cells for 
3+ cases.23 The scoring of the 3+ cases in the present study 
followed the US Food and Drug Administration–approved 
criteria, which require complete membrane staining of strong 
intensity in more than 10% of the tumor cells.23
The results obtained in this present study are in line with 
the results from other large concordance studies published in 
the literature and confirm the close link between HER2 gene 
amplification and overexpression of the HER2 protein. A num-
ber of large HER2 concordance studies performed between 
immunohistochemical analysis and FISH in which the overall 
agreement/concordance has been calculated are listed in ❚Table 
5❚. The overall agreement between the immunohistochemical 
and FISH assays in these studies is in the range of 82.0% to 
98.5%.27-31 None of the data in these studies were analyzed 
exactly in the same way as in the present study, in which 4 
different concordance analyses have been performed. These 
analyses showed that the increase of the cutoff level for amplified/
nonamplified from 2.0 to 2.2, as proposed by the ASCO/CAP 
guidelines,23 resulted in similar concordance between immu-
nohistochemical analysis and FISH. For the whole study 
population (n = 681), the agreement increased from 93.1% to 
94.3%, and for the cohort in which the immunohistochemi-
cally equivocal 2+ cases were excluded, the agreement 
increased from 95.0% to 95.7%.
High concordance between the different immunohis-
tochemical and in situ hybridization assays is important 
because these tests are used as companion diagnostics for the 
selection of patients for treatment with HER2 inhibitors, such 
as trastuzumab and lapatinib. Another even more important 
aspect, which unfortunately has not been addressed properly 
with regard to the use of the HER2 assays as companion diag-
nostics, is the predictive values of these tests in the clinical sit-
uation. In general, a companion diagnostic test will be useful 
only if it provides information that can discriminate between 
responders and nonresponders to the drug in question. For tras-
tuzumab and lapatinib, a large number of clinical studies have 
shown improved treatment outcome when the drugs are used 
in combination with standard therapy in patients with HER2+ 
breast cancer.4-9 With the use of the currently used HER2 
assays, it has been estimated that 30% to 50% of the patients 
respond to the treatment with trastuzumab.32 However, solid 
information on the clinical sensitivity, specificity, and positive 
and negative predictive values of the different HER2 assays 
in the treatment situation is largely unknown. The reason is to 
be found in the design of the clinical trials that have evaluated 
the clinical usefulness of the different HER2 tests. To gener-
ate this type of information, test-positive and test-negative 
subgroups of patients should be included in the clinical trials 
that evaluate the drug-diagnostic combination.33,34 As for the 
HER2 assays, it is not likely that we will gain access to this 
type of information, mainly owing to ethical aspects, but it is 
important that the new drug-diagnostic combinations under 
development take these aspects into consideration when the 
designs of the clinical trials are developed.
❚Table 5❚
HER2 Concordance Studies Between Immunohistochemical 
Analysis and Fluorescence In Situ Hybridization With Overall 
Agreement Calculated*
Study No. of Cases Overall Agreement (%)
Dybdal et al,30 2005 529 82.0
Lal et al,27 2003 561 92.7
Middleton et al,31 2009 1033 98.5†
Yaziji et al,28 2004 1762 96.1‡
Lal et al,29 2004 2279 87.0
Present study 602 95.0‡
* Results of a literature survey of studies with 300 or more patients.
† The cases were scored according to the American Society of Clinical Oncology/
College of American Pathologists guideline with a cutoff value for the HER2/
CEN-17 ratio of 2.2.
‡ 2+ cases were excluded for the analysis.
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Our study shows that the HER2 FISH pharmDx Kit and 
HercepTest are highly concordant with an overall agreement 
around 95%, and it also confirms the close relationship between 
HER2 gene amplification and overexpression of the HER2 
protein in breast carcinoma. The change of the cutoff level for 
amplified/nonamplified cases from 2.0 to 2.2 further does not 
change the concordance between HER2 immunohistochemical 
analysis and FISH. The high concordance between the 2 assays is 
important when they are used routinely as companion diagnostics 
in relation to treatment with trastuzumab and lapatinib.
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